1. Artificial endocrine pancreas with a closed-loop system effectively suppresses the accelerated hyperglycemic status after reperfusion during aortic surgery
- Author
-
Akira Sugaya, Arata Muraoka, Satoshi Uesugi, Soki Kurumisawa, Kei Aizawa, Koji Kawahito, and Hirohiko Akutsu
- Subjects
Blood Glucose ,Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,030204 cardiovascular system & hematology ,Artificial pancreas ,03 medical and health sciences ,Insulin Infusion Systems ,0302 clinical medicine ,Surgical oncology ,medicine ,Humans ,Insulin ,Aged ,Artificial endocrine pancreas ,Glycemic ,business.industry ,General Medicine ,Middle Aged ,Cardiac surgery ,030228 respiratory system ,Cardiothoracic surgery ,Hyperglycemia ,Anesthesia ,Reperfusion ,Circulatory system ,Female ,Surgery ,Cardiology and Cardiovascular Medicine ,business ,Perfusion - Abstract
To control intraoperative hyperglycemia in patients who underwent aortic surgery using STG-55® artificial endocrine pancreas and clarify the effectiveness of this device. Blood glucose control using the STG-55® was performed in 18 patients (15 men and 3 women; age, 66 ± 10 years) who required hypothermic circulatory arrest (STG-55® group). Seventeen patients (10 men and 7 women; age, 71 ± 8 years) whose blood glucose was controlled using the conventional method were included in the control group. Glucose concentration was controlled with the aim of maintaining it at 150 mg/dl. In both groups, the blood glucose concentrations did not significantly change during the interruption of systemic perfusion; however, a sharp increase was noted immediately after reperfusion. Although the hyperglycemic status persisted after reperfusion in the control group, it was effectively suppressed in the STG-55® group (STG® vs. control group at 50 min after reperfusion: 180 ± 35 vs. 212 ± 47 mg/dl, p = 0.026) and blood glucose concentration reached the target value of 150 mg/dl at 100 min after reperfusion (STG® vs. control group: 153 ± 29 vs. 215 ± 43 mg/dl, p = 0.0008). The total administered insulin dose was 175 ± 81 U and 5 ± 3 U in the STG® and control groups, respectively (p
- Published
- 2020
- Full Text
- View/download PDF